Invent Medic Sweden AB has successfully concluded its rights issue, which was significantly oversubscribed, reaching a subscription rate of approximately 145%. This result has allowed the company to raise approximately 5.6 million SEK before deducting issuance costs of about 0.7 million SEK. The conversion from BTA to shares is scheduled for July 15, 2026, with the new shares expected to be available in VP accounts and depots by July 17, 2026. The last trading day for BTA is set for July 13, 2026.

The oversubscription of the rights issue suggests robust investor confidence in Invent Medic's future prospects, reflecting positively on the company's strategic direction and market position. The funds raised are likely to bolster the company's financial position, providing capital for further development and expansion of its innovative medical products.

Despite the positive outcome, potential investors should consider the company's long-term growth strategy and market conditions. The involvement of Aqurat Fondkommission AB as the issuing institution and Klara Stock Market Adviser AB as the project leader underscores the professional management of the rights issue process.

Given the successful capital raise and the strong investor interest, current shareholders might consider holding their positions to benefit from potential future growth. However, new investors should carefully evaluate the company's market strategy and potential risks before committing.

In conclusion, Invent Medic's oversubscribed rights issue is a strong indicator of market confidence, suggesting potential for future growth. Investors are advised to monitor the company's performance closely as it deploys the newly raised capital.